MARKET

FLGT

FLGT

Fulgent Genetics
NASDAQ
17.11
-0.27
-1.55%
After Hours: 17.11 0 0.00% 18:35 05/22 EDT
OPEN
17.33
PREV CLOSE
17.38
HIGH
17.33
LOW
16.76
VOLUME
392.97K
TURNOVER
--
52 WEEK HIGH
31.04
52 WEEK LOW
13.46
MARKET CAP
485.93M
P/E (TTM)
-7.1435
1D
5D
1M
3M
1Y
5Y
1D
Fulgent Genetics Highlights Promising FID-007 Phase 2 Results
TipRanks · 2d ago
Fulgent Genetics' FID-007 Plus Cetuximab Shows 60% Response Rate And 7.2-Month Median PFS In Phase 2 Head And Neck Cancer Study With Favorable Safety Profile
Benzinga · 2d ago
Fulgent posts Phase 2 data: FID-007 plus cetuximab shows 60% ORR in HNSCC
PUBT · 2d ago
FULGENT ANNOUNCES RAPID ORAL FULL ABSTRACT PUBLICATION FOR FID-007 WITHIN THE HEAD AND NECK CANCER TRACK SESSION AT THE ASCO 2026 ANNUAL MEETING
Reuters · 2d ago
Weekly Report: what happened at FLGT last week (0511-0515)?
Weekly Report · 5d ago
Fulgent Genetics Shareholders Approve New 2026 Equity Plan
TipRanks · 05/14 21:45
Weekly Report: what happened at FLGT last week (0504-0508)?
Weekly Report · 05/11 09:52
Fulgent Genetics Price Target Cut to $15.00/Share From $30.00 by Piper Sandler
Dow Jones · 05/05 18:21
More
About FLGT
Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.

Webull offers Fulgent Genetics Inc stock information, including NASDAQ: FLGT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FLGT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FLGT stock methods without spending real money on the virtual paper trading platform.